Fig. 1: Mechanisms of hnRNPA0 and A3 in cancer based on available studies. | Cell Death Discovery

Fig. 1: Mechanisms of hnRNPA0 and A3 in cancer based on available studies.

From: Heterogeneous nuclear ribonucleoprotein A/B: an emerging group of cancer biomarkers and therapeutic targets

Fig. 1

A HnRNPA0 served as a strong promoter for various cancers. MK2-activated hnRNPA0 drove cancer cell drug resistance by regulating p27(Kip1) and Gadd45α. Meanwhile, phosphorylated hnRNPA0 promoted chromosomal alignment by hindering RAB3GAP1-mediated interaction between ZWINT-1 and Rab3. While, the oncogenic effects of hnRNPA0 could be repaired by lncRNA miR205HG. B HnRNPA3 could facilitate cancer progression by affecting EGFR subcellular localization and binding to A3B. In addition, hnRNPA3 was a negative target of EMT regulator miR-200b.

Back to article page